Employment and Labor Market - In 2025, the new urban employment reached 12.67 million, with an average urban survey unemployment rate of 5.2%, indicating overall stability in the employment situation [1] - The Ministry of Human Resources and Social Security plans to implement new employment policies for youth, including college graduates, and enhance recruitment activities [1] - Measures will be taken to support migrant workers and improve employment assistance for vulnerable groups, including veterans [1] Energy Sector - In 2025, 7,084 out of 7,480 key energy-consuming units passed energy measurement reviews, achieving a compliance rate of 94.71% [1] - The energy measurement reviews aim for full coverage of key energy-consuming units during the 14th Five-Year Plan period [1] Financial Sector - The Loan Prime Rate (LPR) for one year is set at 3.0% and for five years or more at 3.5%, remaining unchanged for eight consecutive months [2] - The People's Bank of China indicates there is still room for further reductions in reserve requirements and interest rates [2] Consumer Finance - The implementation period for the personal consumption loan interest subsidy policy has been extended to the end of 2026, with a 1% annual subsidy rate for eligible consumption [4] - The policy now includes credit card installment payments as part of the support scope [4] Tourism Sector - The 2026 version of the team tourism contract template will be implemented nationwide starting March 31, 2026, focusing on enhancing service quality and consumer protection [5] Investment and Economic Development - A special guarantee plan for private investment totaling 500 billion yuan will be implemented over two years to support small and micro enterprises [6] - The plan aims to provide loan guarantees for various business activities, including equipment purchases and digital transformation [6] Pharmaceutical Sector - In 2025, the National Medical Products Administration approved 76 innovative drugs, with 30 of them successfully entering the national medical insurance directory, achieving a coverage rate of 70% for new drugs approved in the first half of the year [6] Fiscal Policy - In 2025, the issuance of ultra-long special government bonds reached 1.3 trillion yuan to support consumption and economic transformation [7] - The funds are allocated for consumer subsidies and to stimulate sales in related sectors, enhancing the quality of life for citizens [7] Regulatory Framework - The National Supervisory Commission will implement the "Regulations on the Disclosure of Supervisory Work Information" starting March 1, 2026, to enhance transparency in supervisory activities [8] Economic Strategy - The National Development and Reform Commission is developing plans to stabilize employment and increase residents' income, which are crucial for boosting domestic demand [8]

Core Viewpoint - The report focuses on the investment opportunities in AI applications, commercial aerospace, and nuclear fusion for 2026, highlighting the performance of the Dividend Low Volatility ETF (512890) amidst a mixed market environment [1][7]. Market Performance - On January 26, A-shares showed mixed results with the Shanghai Composite Index up by 0.12%, while the Shenzhen Component and ChiNext Index experienced declines [1][7]. - The Dividend Low Volatility ETF (512890) rose by 0.52%, closing at 1.154 yuan, with a turnover rate of 1.61% and a transaction volume of 449 million yuan [1][7]. Fund Holdings - The latest quarterly report indicates a mixed performance among the top ten holdings of the Dividend Low Volatility ETF. Notable movements include Shanghai Bank down by 0.21%, Nanjing Bank up by 1.35%, and Gree Electric down by 0.58% [2][9]. - The specific holdings and their market values are as follows: - Shanghai Bank: 781.92 million yuan - Nanjing Bank: 747.01 million yuan (up 32.82%) - Ping An Bank: 712.31 million yuan - Agricultural Bank of Shanghai: 704.49 million yuan - China National Sugar: 690.55 million yuan (down 7.95%) [9]. Fund Flow - The Dividend Low Volatility ETF has seen significant net inflows, with 1.34 billion yuan over the last 5 trading days, 1.88 billion yuan over the last 20 days, and 4.39 billion yuan over the last 60 days. As of January 23, 2026, the fund's circulation scale was 27.845 billion yuan [9]. Investment Strategy - Analysts suggest that the current liquidity environment is a key driver for the spring market rally, supported by new insurance premiums, maturing deposits, and the appreciation of the RMB attracting foreign capital [4][11]. - The report emphasizes the importance of focusing on sectors with strong earnings performance and relatively low price increases, such as AI hardware, batteries, pharmaceuticals, steel, and non-bank financials [11]. - The Dividend Low Volatility strategy is seen as a robust tool for asset allocation in volatile markets, with a three-year return of 36.01%, outperforming its benchmark [12].

Core Viewpoint - The recent IPO strategy shift of Chinese companies, exemplified by Beijing Zhongxi Cultural Media Co., Ltd., indicates a nuanced change in the financing approach for Chinese firms seeking to list in the U.S. market, amidst tightening regulations [1][4]. Group 1: Company-Specific Developments - Beijing Zhongxi Cultural Media has resubmitted its IPO application to the SEC, increasing its fundraising target to approximately $18.75 million, up from a previous plan of $5 million to $6.25 million [1][4]. - The company plans to issue 3.75 million shares at a price range of $4 to $5 per share, doubling the number of shares from the earlier plan of 1.25 million shares [1][3]. - As of mid-2025, Zhongxi Cultural reported revenues of $16.76 million and a net profit of $2.38 million, with major shareholders including Feng Bin and He Xiaoyun [3]. Group 2: Industry Trends - Since June 2025, 11 Chinese companies, including Zhongxi Cultural, have updated their IPO plans, with fundraising amounts primarily ranging from $5 million to $15 million [4]. - The average fundraising size for Chinese companies going public in the U.S. in 2024 was only $50 million, significantly lower than over $300 million in 2021 [4]. - The Nasdaq has proposed new listing standards that significantly raise the IPO thresholds for Chinese companies, with minimum public float market value increasing from $5 million to $15 million, and a minimum fundraising requirement of $25 million for companies primarily operating in China [6]. Group 3: Market Environment - Despite a stricter regulatory environment, enthusiasm for U.S. listings among Chinese companies remains strong, with 57 Chinese companies having gone public in the U.S. since 2025 [8]. - The use of SPACs has increased as a method for Chinese companies to bypass traditional IPO processes, with a notable rise in the number of firms choosing this route in the first half of 2025 [8]. - As of September 2025, 40 Chinese companies had market values below $5 million, which could lead to accelerated delisting processes under the new regulations [11].

Core Insights - The article emphasizes the strategic direction for Baishan City in 2026, aligning with the provincial economic work conference's focus on high-quality development and practical measures for implementation [1][8]. Economic Development - In 2025, Baishan's economy showed positive growth with total investments of 11.7 billion yuan in the construction of the Jingyu pumped storage power station, marking a breakthrough in projects exceeding 10 billion yuan [3]. - The opening of the Shen-Bai high-speed railway and the G331 border tourism corridor significantly boosted the tourism market, with a 30% increase in domestic tourist arrivals [3]. - Key industries such as pharmaceuticals, green food, clean energy, and new materials are thriving, with major economic indicators expected to surpass the provincial average, achieving the best performance in five years [3]. Industry Focus - The city plans to develop its tourism sector by accelerating the construction of key projects like the Yalu River Eye and Xunlong Bay, aiming to enhance the "One Mountain, Two Rivers" brand and introduce 30 seasonal themed tourism routes [3][4]. - The pharmaceutical health industry will be advanced through the implementation of seven empowerment projects for ginseng, establishing a standardized system, and promoting new drug launches [4]. - The green food industry will leverage leading companies to enhance mineral water production and develop high-end organic food products [5]. - Clean energy and new materials sectors will see accelerated projects like the Jingyu pumped storage power station and the exploration of geothermal energy, aiming to create a multi-energy supply system [5]. Social Development - The city is committed to improving people's livelihoods by focusing on employment and income growth, targeting the creation of over 8,000 urban jobs and facilitating the transfer of 55,000 rural laborers [7]. - Rural revitalization efforts will include enhancing the brand influence of local agricultural products and improving rural living environments through targeted actions [7]. - Urban development initiatives will focus on enhancing living quality through city management improvements and infrastructure development [7].

Group 1 - The core point of the article is that Weirui Technology (Suzhou) Co., Ltd. has recently completed its Series A financing round, raising nearly 100 million RMB, with investments from Bainuo Capital and Hongde Investment [1] - Weirui Technology was established in 2021 and is primarily engaged in the pharmaceutical manufacturing industry, located in Suzhou [1] - The company has a registered capital of 7.2558 million RMB and has completed its Series A financing by 2026 [1] Group 2 - The company holds 1 trademark and 37 patents, along with 29 administrative licenses, indicating a strong intellectual property portfolio [1] - The shareholders of Weirui Technology include Nie Xipeng, Suzhou Tongzhou Jianzhang Enterprise Management Partnership, Yangzhou Bainuo Zesheng Venture Capital Partnership, Suzhou Hongde Heshun Venture Capital Partnership, and Suzhou Tongfan Zhiwei Enterprise Management Partnership [1]

Core Viewpoint - Furuike Medical (300049.SZ) has disclosed its performance forecast for 2025, expecting a net profit attributable to shareholders of between 135 million to 164 million yuan, representing a year-on-year growth of 19.17% to 44.77% [1] Financial Performance - The company anticipates a net profit after deducting non-recurring gains and losses to be between 127 million to 166 million yuan, indicating a year-on-year increase of 7.89% to 41.02% [1]

Core Viewpoint - Zhongzhu Medical Holdings Co., Ltd. expects a net profit loss of 100 million to 150 million yuan for the year, with a loss of 110 million to 160 million yuan after excluding non-recurring gains and losses [1][4]. Group 1: Reasons for Loss - The anticipated loss is primarily due to two factors: the impact of the real estate market environment leading to a decline in property prices, resulting in significant asset impairment losses from commercial assets and substantial bad debt provisions for other receivables from joint ventures in commercial real estate projects [4]. - Additionally, the Beijing Loyal Oncology Hospital project has been unable to operate normally, leading to losses, and the company is currently executing a court ruling for its vacating [5]. Group 2: Company Background - Zhongzhu Medical was listed on the Shanghai Stock Exchange in May 2001, with its main business activities including pharmaceutical manufacturing, medical services, medical devices, and real estate [5]. - Zhongzhu Jun Tian (Beijing) Medical Technology Co., Ltd. is a subsidiary of Zhongzhu Medical and is the parent company of Beijing Loyal Oncology Hospital, which has been in a state of pending operation due to disputes over lease contracts and construction contracts since October 2022 [5].

Core Viewpoint - Company ST Zhongzhu (600568) expects a net loss attributable to shareholders of 1 billion to 1.5 billion yuan for the year 2025, an improvement from a loss of 6.2 billion yuan in the previous year [4] Financial Performance - The forecasted net profit loss for 2025 is between 1 billion and 1.5 billion yuan, while the non-recurring net profit loss is expected to be between 1.1 billion and 1.6 billion yuan, compared to a loss of 6.24 billion yuan in the previous year [4] - Historical net profit and non-recurring net profit figures show a consistent decline, with the company reporting a net loss of 6.2 billion yuan in 2023 and 7.99 billion yuan in 2022 [15] - The company's price-to-book ratio (LF) is approximately 3.16 times, and the price-to-sales ratio (TTM) is about 9.5 times based on the latest closing price [4] Business Operations - The company's main business areas include pharmaceutical manufacturing, medical services, medical devices, and real estate [14] - The decline in performance is attributed to the impact of the real estate market environment, leading to a decrease in property prices and significant asset impairment losses from commercial assets [14] - The Beijing Loyal Oncology Hospital project has incurred losses due to its inability to operate normally, and the company is currently executing a court ruling for its vacating [14]

Group 1 - The China International Import Expo (CIIE) has become a significant platform for global companies to access the Chinese market, with a record number of participating enterprises and an intention to achieve over $80 billion in transactions during the eighth edition of the expo [12][11][10] - Romania's REPUBLIKA sunflower oil has gained attention as a star product in the Chinese market, showcasing successful bilateral cooperation between China and Romania [5][1] - Belarusian dessert manufacturer "Vitba" has been actively investing in the Chinese market, leveraging the rapid growth of e-commerce and participating in major trade events like CIIE to enhance market presence [5][6] Group 2 - The eighth CIIE has introduced a dedicated section for products from least developed countries, attracting 163 companies, a 23.5% increase year-on-year, highlighting China's commitment to supporting global southern economies [17] - The Chinese government aims to balance trade development and enhance import facilitation through various platforms, including CIIE, to better meet industrial and consumer needs [11][16] - The participation of 125 Canadian companies in the eighth CIIE marks a historical high, reflecting the strong trade relationship between China and Canada, with bilateral trade reaching $10 billion in the first 11 months of 2025 [24]

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].